CVKD: New Blood Thinner Ready for Phase 3 Initiating Coverage of Cadrenal Therapeutics Inc
We are initiating coverage of Cadrenal Therapeutics, Inc. (CVKD) with a valuation of $30.00. Cadrenal is a clinical stage biopharmaceutical...
Cadrenal Therapeutics Inc - September 16, 2024
We are initiating coverage of Cadrenal Therapeutics, Inc. (CVKD) with a valuation of $30.00. Cadrenal is a clinical stage biopharmaceutical...
No more insights